Skip to main content

Advertisement

SpringerLink
Log in

Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

Mean platelet volume (MPV) is one of the four platelet parameters (platelet count, MPV, platelet distribution width and plateletcrit), which indicates the activation of platelet. We aim to investigate the associations between pre-treatment MPV levels and clinical hematology parameters, pathology parameters and prognosis of patients with invasive breast cancer (IBC).

Methods

Medical records of 340 breast tumor patients (170 IBC vs. 170 breast benign tumor) were retrospectively reviewed. Patients in two groups were matched for age, body mass index, smoking status and complications. To analyze: differences in pre-treatment MPV levels between IBC group and breast benign tumor group; differences between pre- and postoperative MPV levels in IBC patients; correlations between pre-treatment MPV and clinical hematology parameters, clinicopathologic parameters and prognosis in IBC patients.

Results

As we analyzed, pre-treatment MPV levels of IBC patients were significantly higher than the controls (8.65 ± 0.98 vs 8.34 ± 0.78, P = 0.002), and preoperative MPV levels were significantly higher than the postoperative in IBC patients (8.65 ± 0.98 vs 8.44 ± 0.91, P = 0.042). In IBC group, pre-treatment MPV level associated, significantly, with clinical hematology parameters (platelet, fibrinogen, albumin, fasting blood glucose, P = 0.003, 0.042, 0.032, 0.046, respectively) and with clinicopathological parameters (distant metastasis, primary tumor size, tumor node metastasis stages, P = 0.039, 0.002, 0.001, respectively). Furthermore, univariate and multivariate survival analysis demonstrated that MPV was significant prognostic factor (P = 0.035, HR 1.86, 95 % confidence interval 1.06–3.25).

Conclusion

High pre-treatment MPV level in IBC patients was a potential predictive factor and significant independent prognostic factor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Tran BH, Joanna Nguyen T, Hwang BH, Vidar EN, Davis GB, Chan LS, et al. Risk factors associated with venous thromboembolism in 49,028 mastectomy patients. Breast. 2013;22(4):444–8.

    Article  PubMed  Google Scholar 

  2. Andtbacka RH, Babiera G, Singletary SE, Hunt KK, Meric-Bernstam F, Feig BW, et al. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg. 2006;243(1):96–101.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Clahsen PC, van de Velde CJ, Julien JP, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European organization for research and treatment of cancer breast cancer cooperative group study. J Clin Oncol. 1994;12(6):1266–71.

    CAS  PubMed  Google Scholar 

  4. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320(8):479–84.

    Article  CAS  PubMed  Google Scholar 

  5. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–46.

    Article  PubMed  Google Scholar 

  6. Wedgwood KR, Benson EA. Non-tumour morbidity and mortality after modified radical mastectomy. Ann R Coll Surg Engl. 1992;74(5):314–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Karpatkin S, Pearlstein E, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest. 1988;81:1012–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Biggerstaff JP, Seth N, Amirkhosravi A, Amaya M, Fogarty S, Meyer TV, et al. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis. Clin Exp Metastasis. 1999;17:723–30.

    Article  CAS  PubMed  Google Scholar 

  9. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA. 2001;98:3352–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol. 2009;22(1):49–60.

    Article  CAS  PubMed  Google Scholar 

  11. Jakubowski JA, Thompson CB, Vaillancourt R, Valeri CR, Deykin D. Arachidonic acid metabolism by platelets of differing size. Br J Haematol. 1983;53:503–11.

    Article  CAS  PubMed  Google Scholar 

  12. Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet. 1991;338:1409–11.

    Article  CAS  PubMed  Google Scholar 

  13. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:148–56.

    Article  CAS  PubMed  Google Scholar 

  14. Greisenegger S, Endler G, Hsieh K. Is high mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke. 2004;35:1688–91.

    Article  CAS  PubMed  Google Scholar 

  15. Kapsoritakis AN, Koukourakis MI, Sfiridaki Potamianos SP, Kosmadaki MG, Koutroubakis IEA, et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol. 2001;96(3):776–81.

    Article  CAS  PubMed  Google Scholar 

  16. Kisacik Bunyamin, Tufan Abdurrahman, Kalyoncu Umut, Karadag O, Akdogan A, Ozturk MA, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Jt Bone Spine. 2008;75:291–4.

    Article  Google Scholar 

  17. Kurt M, Onal IK, Sayilir AY, Beyazit Y, Oztas E, Kekilli M, et al. The role of mean platelet volume in the diagnosis of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology. 2012;59(117):1580–2.

    CAS  PubMed  Google Scholar 

  18. Jia-Ying Li, Ying Li, Zheng Jiang, Rui-Tao Wang, Xi-Shan Wang, et al. High mean platelet volume is associated with presence of colon cancer. Asian Pac J Cancer Prev. 2014;15(23):10501–4.

    Google Scholar 

  19. Matowicka-Karna Joanna, Kamocki Zbigniew, PoliNska Beata, Osada J, Kemona H. Platelets and inflammatory markers in patients with gastric cancer. Clin Dev Immunol. 2013;2013:401623–8.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Inagaki N, Kibata K, Tamaki T, Shimizu T, Nomura S. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer. 2014;83(1):97–101.

    Article  PubMed  Google Scholar 

  21. Karaman K, Bostanci EB, Aksoy E, Kurt M, Celep B, Ulas M, et al. The predictive value of mean platelet volume in differential diagnosis of non-functional pancreatic neuroendocrine tumors from pancreatic adenocarcinomas. Eur J Intern Med. 2011;22(6):e95–8.

    Article  PubMed  Google Scholar 

  22. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract. 2009;63(10):1509–15.

    Article  CAS  PubMed  Google Scholar 

  23. Lancé MD, van Oerle R, Henskens YM, Marcus MA. Do we need time adjusted mean platelet volume measurements? Lab Hematol. 2010;16(3):28–31.

    Article  PubMed  Google Scholar 

  24. Berger FG. The interleukin-6 gene: a susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality. Breast Cancer Res Treat. 2004;88:281–5.

    Article  CAS  PubMed  Google Scholar 

  25. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001;102:V215–24.

    Article  CAS  PubMed  Google Scholar 

  26. Riedl J, Kaider A, Reitter EM, Marosi C, Jäger U, Schwarzinger I, et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS). Thromb Haemost. 2014;111(4):670–8.

    Article  CAS  PubMed  Google Scholar 

  27. Mutlu H, Artis TA, Erden A, Akca Z. Alteration in mean platelet volume and platicrit values in patients with cancer that developed thrombosis. Clin Appl Thromb Hemost. 2013;19(3):331–3.

    Article  PubMed  Google Scholar 

  28. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105:178–85.

    Article  CAS  PubMed  Google Scholar 

  29. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Hekimsoy Z, Payzin B, Ornek T, Kandofan G. Mean platelet volume in type 2 diabetic patients. J Diabetes Complicat. 2004;18(3):173–6.

    Article  PubMed  Google Scholar 

  31. Papanas N, Symeonidis G, Maltezos E, Mavridis G, Karavageli E, Vosnakidis T, et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2004;15:475–8.

    Article  CAS  PubMed  Google Scholar 

  32. Kuderer NM, Khorana AA, Lyman GH, Francis CW, et al. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 2007;110:1149–61.

    Article  CAS  PubMed  Google Scholar 

  33. Lazo-Langner A, Goss GD, Spaans JN, Hodsman A, Kovacs MJ, Clement AM, et al. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost. 2007;5:729–37.

    Article  CAS  PubMed  Google Scholar 

  34. Falanga A, Piccioli A. Effect of anticoagulant drugs in cancer. Curr Opin Pulm Med. 2005;11:403–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by Natural Science Foundation Project of Liaoning Province (No. 2010010280-401).

Author information

Authors and Affiliations

  1. Department of Oncology, The First Affiliated Hospital of Liaoning Medical University, No. 2, The Fifth Section of Renmin Street, Guta, Jinzhou, 121000, Liaoning, China

    Meiling Gu & Caijun Yuan

  2. Department of Oncology Tumour Angiogenesis and Microenvironment Laboratory, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, 121000, Liaoning, China

    Zhenhua Zhai

  3. Institute of Biological Anthropology Research, Liaoning Medical University, Jinzhou, 121000, Liaoning, China

    Li Huang

  4. Department of Immunology, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, 121000, Liaoning, China

    Wenjiao Zheng

  5. Department of Breast Surgeon, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, 121000, Liaoning, China

    Yichao Zhou

  6. Department of Laboratory, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, 121000, Liaoning, China

    Ruiqi Zhu

  7. Department of Pathology, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, 121000, Liaoning, China

    Feifei Shen

Authors
  1. Meiling Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhenhua Zhai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenjiao Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yichao Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ruiqi Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Feifei Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Caijun Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caijun Yuan.

Ethics declarations

Conflict of interest

None.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gu, M., Zhai, Z., Huang, L. et al. Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer. Breast Cancer 23, 752–760 (2016). https://doi.org/10.1007/s12282-015-0635-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-015-0635-6

Keywords

Search

Navigation